eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 15
Clinical research

Vitreous concentrations of vascular endothelial growth factor as a potential biomarker for postoperative complications following pars plana vitrectomy

Faruk Nisic, Nina Jovanovic, Milka Mavija, Emina Alimanovic-Halilovic, Aida Nisic, Orhan Lepara, Adem Cemerlic

Arch Med Sci 2019; 15, 2: 449–456
Online publish date: 2018/02/02
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
The aim of the study was to investigate the effects of vascular endothelial growth factor (VEGF) concentration in vitreous on postoperative complications after pars plana vitrectomy (PPV).

Material and methods
Ninety subjects were surgically treated with PPV and followed up for 12 months at the Clinical Centre University Sarajevo, Clinic for Eye Disease. Exclusion criteria were presence of other eye diseases, systemic acute/chronic inflammatory conditions, or malignant neoplasms; previously performed PPV surgery; previously received intravitreal or systemic anti-VEGF therapy. A vitreous sample was obtained while performing the PPV procedure, using the Quantikine ELISA test to determine VEGF level, as a risk factor. Outcome measures were intraoperative and postoperative complications reported using categorical data: blunt and sharp dissection of membranes, intraoperative hemorrhage stopped by increasing infusion pressure, pressing with blunt instrument, or using diathermy. The following postoperative complications were assessed on the first day and at the 12-month follow-up visit: vitreous hemorrhage, fibrovascular proliferation (FVP), rubeosis iridis, and neovascular glaucoma (NVG).

Levels of vitreous VEGF at the time of PPV were significantly higher in eyes with: vitreous hemorrhage on the first day after PPV (p = 0.003); FVP on the first day and 12 months after PPV (p = 0.002 and p < 0.001, respectively); iris rubeosis on the first day and 12 months after PPV surgery (p < 0.001, and p = 0.001, respectively); NVG on the first day and 12 months after PPV surgery (p = 0.043 and p = 0.011, respectively), compared to the eyes without complications.

Preoperative levels of VEGF in vitreous can be a useful biomarker and predictor of the postoperative outcome in terms of intraoperative and postoperative complications.


vascular endothelial growth factor, pars plana vitrectomy, proliferative diabetic retinopathy, postoperative complications, biomarker

Lai FH, Lo EC, Chan VC, Brelen M, Lo WL, Young AL. Combined pars plana vitrectomy-scleral buckle versus pars plana vitrectomy for proliferative vitreoretinopathy. Int Ophthalmol 2016; 36: 217-24.
Abouammoh MA, Abouammoh MA, Gale JS, Arevalo JF, Sharma S. A novel technique for securing sclerotomies in 20-gauge transconjunctival pars plana vitrectomy: surgical outcomes and complications in 529 consecutive cases. Retina 2016; 36: 974-80.
Chao D, Gonzalez M, Flynn H. Giant retinal tears after pars plana vitrectomy for diabetic vitreous hemorrhage. Retin Physician 2012; 9: 40-2.
Steve C. Complications of diabetic vitreoretinal surgery. Retin Physician 2010; 7: 41-6.
Canavese M, Spaccapelo R. Protective or pathogenic effects of vascular endothelial growth factor (VEGF) as potential biomarker in cerebral malaria. Pathog Glob Health 2014; 108: 67-75.
Mehta LJ, Dhalla NS. Biochemical Basis and Therapeutic Implications of Angiogenesis. Springer International Publishing, New York 2013.
Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29: 10-4.
Fogli S, Mogavero S, Egan CG, Del Re M, Danesi R. Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. Pharmacol Res 2016; 103: 149-57.
Amadio M, Govoni S, Pascale A. Targeting VEGF in eye neovascularization: What’s new? A comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol Res 2016; 103: 253-69.
Wakabayashi Y, Usui Y, Okunuki Y, et al. Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2012; 53: 6403-10.
Funatsu H, Yamashita H, Miura T, Noma H, Nakamura S, Hori S. Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines. Eye 2007; 21: 377-82.
Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology 2007; 114: 710-5.
Yan H, Cui J, Yu JG, et al. The expression of vascular endothelial growth factor of vitreous in patients with proliferative diabetic retinopathy. Zhonghua Yan Ke Za Zhi 2009; 45: 206-9.
Smith JM, Steel DHW. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity hemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2011; 5: CD008214.
Oshima Y, Shima C, Wakabayashi T, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology 2009; 116: 927-38.
Wirostko B, Wong TY, Simo R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res 2008; 27: 608-21.
Moradian S, Ahmadieh H, Malihi M, Soheilian M, Dehghan MH, Azarmina M. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefe’s Arch Clin Exp Ophthalmol 2008; 246: 1699-705.
Carrasco E, Garrido JM, Álvarez PJ, et al. Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells. Arch Med Sci 2016; 12: 919-27.
Tu Y, Fay C, Guo S, Zarbin MA, Marcus E, Bhagat N. Ranibizumab in patients with dense cataract and proliferative diabetic retinopathy with rubeosis. Oman J Ophthalmol 2012; 5: 161-5.
Salman AG. Intrasilicone bevacizumab injection for iris neovascularization after vitrectomy for proliferative diabetic retinopathy. Ophthalmic Res 2013; 49: 20-4.
Shen X, Chen Y, Wang Y, Yang L, Zhong Y. Intravitreal ranibizumab injection as an adjuvant in the treatment of neovascular glaucoma accompanied by vitreous hemorrhage after diabetic vitrectomy. J Ophthalmol 2016; 2016: 4108490.
Lanzl I, Kotliar K. Can anti-VEGF injections cause glaucoma or ocular hypertension? Klin Monbl Augenheilkd 2017; 234: 191-3.
Sayan S, Kotan D. Levels of brain natriuretic peptide as a marker for the diagnosis and prognosis of acute ischemic stroke. Arch Med Sci Atheroscler Dis 2016; 1: e16-22.
Das UN. Diabetic macular edema, retinopathy and age-related macular degeneration as inflammatory conditions. Arch Med Sci 2016; 12: 1142-57.
Senel K, Baykal T, Seferoglu B, et al. Circulating vascular endothelial growth factor concentrations in patients with postmenopausal osteoporosis. Arch Med Sci 2013; 9: 709-12.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe